S5 Ep76: ctDNA Monitoring is a Piece of the Puzzle in CRC Treatment cover art

S5 Ep76: ctDNA Monitoring is a Piece of the Puzzle in CRC Treatment

S5 Ep76: ctDNA Monitoring is a Piece of the Puzzle in CRC Treatment

Listen for free

View show details

About this listen

 In this episode of The Vitals, Holly Chitwood, DNP, FNP-C, AGACNP-BC, walks through a patient case with a 70-year-old male with metastatic colorectal cancer.1 His providers used circulating tumor DNA (ctDNA) testing to monitor his minimal residual disease (MRD) levels throughout active treatment. This approach, although not currently addressed in National Comprehensive Cancer Center Guidelines, allows patients and providers to have an idea of how the treatment is working earlier compared with what imaging can usually demonstrate, she explains.

Chitwood is an assistant professor in the College of Nursing at the University of Kentucky, as well as a practicing oncology APRN who primarily cares for patients with gastrointestinal, hepatic-biliary, and sarcoma tumors in her clinic. To read the full case study, please check out our show notes below.

Episode Highlights

“This is a new technology that we have. It is basically looking at what is in your blood to see how much circulating tumor DNA is floating around.”

“In this case, and in a lot of my patients, you will see ctDNA is about, you know, anywhere from 2 to 3 months [ahead], predating what you will see on imaging.”

“You have to be very judicious in explaining the results, especially if you have a positive result, and the patient should be included in the decision making.”

Online Articles

  • ctDNA Continues to Emerge As A Potentially Useful Disease Monitoring Tool in CRC
  • ctDNA Makes Headway as Promising Marker for Patients With Anal Cancer and Other GI Malignancies
  • ESMO Guideline on Liquid Biopsy Address Quality Standards for Clinical Implementation
  • New Treatment Methods Launch a Shift in CRC Treatment

Videos

  • Metastatic CRC Nursing Webinar

Podcast

  • Terri Pollack Offers Perspective on 2023 ASCO GI Cancers Symposium
  • Overcome Screening Barriers in CRC

References

  1. Chitwood H, Myers A. Use of circulating tumor DNA to monitor minimal residual disease among patients with colorectal cancer. Clin J Oncol Nurs. 2023;27(4):369-374. doi:10.1188/23.CJON.369-374

What listeners say about S5 Ep76: ctDNA Monitoring is a Piece of the Puzzle in CRC Treatment

Average Customer Ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com.au reviews

Amazon Reviews
No Reviews are Available
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.